Trogenix raises £70m Series A led by IQ Capital to advance precision cancer therapies into clinical trials

Trogenix develops precision genetic medicines for aggressive solid tumours, using targeted delivery systems designed to kill cancer cells and stimulate immune responses while limiting damage to healthy tissue.